Immunohistochemical detection of Fas and Fas ligand in sarcomatoid renal cell carcinoma

被引:5
作者
Leroy, X
Wacrenier, A
De La Taille, A
Gosset, P
Saint, F
Biserte, J
Gosselin, B
机构
[1] Univ Hosp Lille, Dept Pathol, Lille, France
[2] Univ Hosp Lille, Dept Urol, Lille, France
关键词
kidney; sarcomatoid carcinoma; Fas; Fas ligand; immunohistochemistry;
D O I
10.1034/j.1600-0463.2001.090610.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sarcomatoid renal cell carcinomas (SRC) are rare neoplasms associated with a very poor prognosis. The aim of this study was to evaluate biomarker expression and clinical significance in this uncommon renal cancer. Cytokeratin, epithelial membrane antigen, vimentin, desmin, smooth muscle actin, CD34, S-100 protein, MIB 1, p53, Fas and Fas ligand immunohistochemical expression was investigated in seven renal cell carcinomas with sarcomatoid changes. No significant difference between sarcomatoid and nonsarcomatoid areas was observed with the different biomarkers, excepted for Fas ligand. Fas expression was diffuse in sarcomatoid and nonsarcomatoid areas. However, Fas ligand had a higher expression in sarcomatoid in comparison to nonsarcomatoid areas. Our results showed that Fas and Fas ligand are both expressed in renal cancer. We suggest that the aggressive behavior of sarcomatoid carcinoma may be related to a higher expression of Fas ligand by tumor sarcomatoid cells. These findings may indicate that Fas ligand is a possible therapeutic molecular target for treatment of SRC.
引用
收藏
页码:469 / 473
页数:5
相关论文
共 19 条
  • [1] Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy
    Cangiano, T
    Liao, J
    Naitoh, J
    Dorey, F
    Figlin, R
    Belldegrun, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 523 - 528
  • [2] TREATMENT OF SARCOMATOID RENAL-CELL CARCINOMA - IS THERE A ROLE FOR CHEMOTHERAPY
    CULINE, S
    BEKRADDA, M
    TERRIERLACOMBE, MJ
    DROZ, JP
    [J]. EUROPEAN UROLOGY, 1995, 27 (02) : 138 - 141
  • [3] Sarcomatoid renal carcinoma: The final common dedifferentiation pathway of renal epithelial malignancies
    Delahunt, B
    [J]. PATHOLOGY, 1999, 31 (03) : 185 - 190
  • [4] Gerharz CD, 1999, LAB INVEST, V79, P1521
  • [5] GREEN DR, 1997, P NATL ACAD SCI USA, V18, P240
  • [6] Expression of Fas in renal cell carcinoma
    Horie, S
    Kano, M
    Higashihara, E
    Moriyama, N
    Tanaka, E
    Hirose, A
    Kakizoe, T
    Kawabe, K
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (06) : 384 - 388
  • [7] Immunohistochemical expression of p53 and bcl-2 proteins is not associated with sarcomatoid change in renal cell carcinoma
    Kanamaru, H
    Li, BY
    Miwa, Y
    Akino, H
    Okada, K
    [J]. UROLOGICAL RESEARCH, 1999, 27 (03): : 169 - 173
  • [8] Kim YS, 2000, ARCH PATHOL LAB MED, V124, P687
  • [9] Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients
    Kimura, M
    Tomita, Y
    Imai, T
    Saito, T
    Katagiri, A
    Tanikawa, T
    Takeda, M
    Takahashi, K
    [J]. BRITISH JOURNAL OF CANCER, 1999, 80 (10) : 1648 - 1651
  • [10] Immunohistochemical analysis of Fas ligand expression in normal human tissues
    Lee, SH
    Shin, MS
    Park, WS
    Kim, SY
    Dong, SM
    Lee, HK
    Park, JY
    Oh, RR
    Jang, JJ
    Lee, JY
    Yoo, NJ
    [J]. APMIS, 1999, 107 (11) : 1013 - 1019